NBIX vs. TECH, XLRN, QGEN, MNTA, BIIB, ALNY, BMRN, INCY, UTHR, and EXAS
Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Bio-Techne (TECH), Acceleron Pharma (XLRN), Qiagen (QGEN), Momenta Pharmaceuticals (MNTA), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), United Therapeutics (UTHR), and Exact Sciences (EXAS). These companies are all part of the "medical" sector.
Neurocrine Biosciences (NASDAQ:NBIX) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking.
Neurocrine Biosciences has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.
In the previous week, Neurocrine Biosciences had 1 more articles in the media than Bio-Techne. MarketBeat recorded 18 mentions for Neurocrine Biosciences and 17 mentions for Bio-Techne. Neurocrine Biosciences' average media sentiment score of 0.84 beat Bio-Techne's score of 0.51 indicating that Neurocrine Biosciences is being referred to more favorably in the media.
Neurocrine Biosciences has a net margin of 18.65% compared to Bio-Techne's net margin of 17.59%. Neurocrine Biosciences' return on equity of 17.45% beat Bio-Techne's return on equity.
Neurocrine Biosciences received 605 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.70% of users gave Neurocrine Biosciences an outperform vote while only 62.38% of users gave Bio-Techne an outperform vote.
92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 4.5% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Bio-Techne has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Neurocrine Biosciences presently has a consensus price target of $154.08, indicating a potential upside of 4.99%. Bio-Techne has a consensus price target of $81.00, indicating a potential upside of 0.68%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Bio-Techne.
Summary
Neurocrine Biosciences beats Bio-Techne on 13 of the 19 factors compared between the two stocks.
Get Neurocrine Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurocrine Biosciences Competitors List
Related Companies and Tools
